Figure 4.

Steady state ErbB2 distribution is not significantly affected by trastuzumab or pertuzumab. SKBr3 cells were incubated with 647-Tf for 3.5 h at 37°C in the absence (top row) or presence of 10 μg/ml 488-trastuzumab (middle row) or 488-pertuzumab (bottom row). Cells were then fixed and processed for indirect immuno-epifluorescence microscopy using an antibody recognizing the cytoplasmic tail of ErbB2 (second panels). Scale bars, 20 μM.